menu
    • menu
    [{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cryopreserved Platelet","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellphire Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cryopreserved Platelet","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellphire Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"6","companyTruncated":"Cellphire Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Hematology","graph2":"Undisclosed","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cellphire Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Human Platelets","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"9","companyTruncated":"Cellphire Therapeutics \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Simcah Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Cellphire Therapeutics \/ Simcah Management","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Simcah Management"},{"orgOrder":0,"company":"Cellphire Therapeutics","sponsor":"Jakob Stensballe","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Thrombosomes","moa":"Platelet level","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cellphire Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellphire Therapeutics \/ Jakob Stensballe","highestDevelopmentStatusID":"8","companyTruncated":"Cellphire Therapeutics \/ Jakob Stensballe"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellphire Therapeutics

    Menu

    Cellphire Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Platelet

                            Therapeutic Area : Hematology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellphire Stops Phase 2/3 CRYPTICS Study Early for Efficacy

                            Details : CLPH-511, Cellphire’s investigational cryopreserved platelet product (CPP), is being developed for the treatment of uncontrolled hemorrhage in patients undergoing cardiopulmonary bypass surgery.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : Cryopreserved Platelet

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cryopreserved Platelet

                            Therapeutic Area : Hematology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellphire Therapeutics CLPH-511 Fast Track Designation Granted

                            Details : CLPH-511 (frozen activated platelets) injectable suspension is being evaluated for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Cryopreserved Platelet

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Jakob Stensballe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thrombosomes® in Acute Thoracic Aortic Dissections

                            Details : Thrombosomes is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dissection, Thoracic Aorta.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 16, 2023

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Jakob Stensballe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Simcah Management

                            Deal Size : $15.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Management

                            Details : This financing round enables Cellphire to expand and accelerate the development of Thrombosomes® and support the company's groundbreaking research and development projects in the areas of targeted drug delivery, anti-thrombotic reversal, and regenerativ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 02, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Simcah Management

                            Deal Size : $15.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Platelets

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II/ Phase III

                            Sponsor : U.S. Army Medical Research and Development Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)

                            Details : Human Platelets is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 14, 2021

                            Lead Product(s) : Human Platelets

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : U.S. Army Medical Research and Development Command

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thrombosomes® in Bleeding Thrombocytopenic Patients Study

                            Details : Thrombosomes is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thrombosomes for Expanded Access Use

                            Details : Thrombosomes is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Hemorrhage.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 06, 2020

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Thrombosomes® in Bleeding Thrombocytopenic Patients

                            Details : Thrombosomes is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 09, 2018

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cellphire Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microd...

                            Details : Thrombosomes is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 22, 2014

                            Lead Product(s) : Thrombosomes

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Department of Health and Human Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth